Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of Resistance-Associated Mutations After Sotrovimab Administration in High-risk Individuals Infected With the SARS-CoV-2 Omicron Variant.

JAMA - 20 Sept 2022

Birnie Emma, Biemond Jason J, Appelman Brent, de Bree Godelieve J, Jonges Marcel, Welkers Matthijs R A, Wiersinga W Joost

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antibodies, Neutralizing
Share to COVID-19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to COVID-19 Drug Treatment

Share to Drug Resistance, Viral

Share to Mutation

Share to SARS-CoV-2

Share to SARS-CoV-2 and COVID-19 Research

Source

Open in PubMed Open full text

Identifiers

PMID: 35913747
DOI: 10.1001/jama.2022.13854
PMCID: PMC9344387

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of Resistance-Associated Mutations After Sotrovimab Administration in High-risk Individuals Infected With the SARS-CoV-2 Omicron Variant.PMID 35913747Read ↗

Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimabSemantic proximity Read ↗

Resistance mutations in SARS-CoV-2 omicron variant after tixagevimab-cilgavimab treatmentSemantic proximity Read ↗

Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patientsSemantic proximity Read ↗

Frequent Emergence of Resistance Mutations Following Complex Intra-Host Genomic Dynamics in SARS-CoV-2 Patients Receiving Sotrovimab.Semantic proximity Read ↗

Frequent emergence of resistance mutations following complex intra-host genomic dynamics in SARS-CoV-2 patients receiving SotrovimabSemantic proximity Read ↗

Sotrovimab drives SARS-CoV-2 Omicron variant evolution in immunocompromised patientsSemantic proximity Read ↗

Longitudinal Analysis of Escape Mutations in SARS-CoV-2 Omicron Variants after Sotrovimab Use in Immunodeficient PatientsSemantic proximity Read ↗

Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxisSemantic proximity Read ↗

High incidence of sotrovimab resistance and viral persistence after treatment of immunocompromised patients infected with the SARS-CoV-2 Omicron variantSemantic proximity Read ↗

RESISTANCE CONFERRING MUTATIONS IN SARS-CoV-2 DELTA FOLLOWING SOTROVIMAB INFUSIONSemantic proximity Read ↗

Multidrug-resistant mutations to antiviral and antibody therapy in an immunocompromised patient infected with SARS-CoV-2.Semantic proximity Read ↗

Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that emerge after treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.